Tumor drainage lymph node identification and dissection are crucial for the oncological surgery to prevent/delay the recurrence. However, commercial imaging reagents distinguish the lymph nodes by staining them dark, which would be seriously interfered by blood and surrounding tissues. In this study, we reported the Cr/Pr-doped zinc gallogermanate persistent luminescent nanoparticles (PLNPs) for fast tumor drainage lymph node imaging with high contrast. PLNPs were synthesized by citrate sol-gel method and dispersed in Tween 80 for in vivo applications. PLNPs were well dispersed in water with hydrodynamic radii of 5 nm and emitted strong persistent luminescence at 696 nm upon the irradiation of UV light. The advantage of afterglow imaging over fluorescent imaging of PLNPs was first established after subcutaneous injection to mice with much higher contrast and less interference of autofluorescence. PLNPs quickly migrated to sentinel lymph nodes after the interdermal injection to extremity of mice. The tumor drainage lymph node imaging was achieved within 5 min upon the intratumoral injection to H460 tumor bearing mice and the signal to noise ratio was 462. Due to the lack of targeting moieties, the intravenous injected PLNPs mainly accumulated in liver. There were no statistical changes in serum biochemistry and abnormal histopathological characteristic, indicating the low toxicity of PLNPs. These findings highlighted the great potential of PLNPs as high-performance imaging reagent for lymph node identification.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.colsurfb.2021.111887 | DOI Listing |
Clin J Gastroenterol
December 2024
Department of Diagnostic Pathology, National Hospital Organization Shizuoka Medical Center, 762-1 Nagasawa, Shimizu, Sunto District, Shizuoka, 411-0904, Japan.
Surgical resection is the only curative treatment for cholangiocarcinoma, but it is often diagnosed at advanced stages, making surgical resection infeasible. Recently, the concept of conversion surgery has expanded the indications for surgical treatment, thanks to advancements in both perioperative management and chemotherapy. However, it remains unclear which patients benefit most from this treatment strategy.
View Article and Find Full Text PDFAnn Med
December 2025
Department of General Surgery, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
Objective: To comprehensively investigate the predictive value of thyroid hormone sensitivity parameters for cervical lymph node metastasis in patients diagnosed with differentiated thyroid cancer (DTC) undergoing total thyroidectomy and neck lymph node dissection.
Methods: A retrospective cohort study was conducted involving patients diagnosed with DTC and evaluated for cervical lymph node metastasis. Relevant demographic, tumour, lymph node and thyroid hormone sensitivity parameter data were extracted from medical records and laboratory reports.
Thorac Cancer
December 2024
Breast Disease Center, Peking University People's Hospital, Beijing, China.
Background: Sentinel lymph node biopsy (SLNB) using radioisotope tracer plus blue dye is the gold standard after neoadjuvant chemotherapy (NAC) in initially cN1 breast cancer patients, but clinical use still has limitations. This study aims to examine diagnostic performance of dual indocyanine green (ICG) and methylene blue tracing for SLNB in patients who have completed NAC for breast cancer with initially cN1 disease.
Methods: Adult women (20-80 years of age) scheduled to undergo NAC for biopsy-proven cT0-3N1M0 primary invasive breast cancer were consecutively enrolled in this prospective, multicenter, cohort study.
Histopathology
December 2024
Goethe University Frankfurt, Medical Clinic 1, University Hospital, Frankfurt am Main, Germany.
Aims: Anti-claudin-18.2 (CLDN18.2) therapy was recently approved for the treatment of gastric or gastro-oesophageal junction adenocarcinoma.
View Article and Find Full Text PDFBMC Cancer
December 2024
Department of Pathology, Fudan University Shanghai Cancer Center, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Background: Male breast cancer (MBC) is a rare malignancy, but its global incidence has shown a notable increase in recent decades. Factors such as limited health literacy, inadequate health education, and reluctance to seek medical attention contribute to the late-stage diagnosis of most MBC patients. Consequently, there is an urgent need for a highly specific and sensitive diagnostic approach to MBC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!